Why This 1 Cannabis Stock Sticks Out Like a Sore Thumb

It was popular for a while to refer to the cannabis space as another dot-com bubble. There were definitely similarities: a new industry full of potential was getting investors exciting, driving up share prices until the bubble burst. Post-legalization, many of the great green hopes touted by early cannabis bulls were up in smoke, to use a tired idiom. But…

Read More

Is Namaste Technologies’ Stock a Buy After Reporting Record Quarterly Revenue?

It once aspired to be “the Amazon of cannabis,” but e-commerce focused marijuana stock Namaste Technologies (TSXV:N) has taken on a manufacturing-based growth strategy that’s beginning to yield impressive results. The company has shaken off its drama-filled past. Operations have returned to strong sequential quarterly sales growth. Actually, the company reported record quarterly revenue in last week’s earnings release. Should…

Read More

TFSA Investors: 3 Reasons to Buy Aphria Stock Today

Cannabis firm Aphria’s (TSX:APHA)(NASDAQ:APHA) stock price rallied to close 9% higher on Monday after W. Andrew Carter, a respected equity analyst at Stifel Financial, upgraded the top marijuana stock from a Hold to a Buy and increased his price target. The analyst’s US$5.90 new price target on APHA shares implied a 26% upside from the company’s previous share price at…

Read More

Market Crash Alert: How the Cannabis Bubble Affects All Stocks

Investors that have lost their shirts with various Canadian cannabis stocks over the past year can attest the pain of a bubble and stock prices. Valuations are now at levels that, by some metrics, are at all-time highs. Therefore, investors ought to be more cautious with making large investments in any company right now. In this article, I’m going to…

Read More

Cronos Group (TSX:CRON) Stock: 1 Management Decision That Delays Growth in the U.S. Market

Cronos Group (TSX:CRON)(NASDAQ:CRON) finally reported its delayed fourth0quarter and full-year 2019 results on March 30. Much to investors’ disappointment, the company’s quarterly revenue growth in Canada was negative and massive inventory charges drowned spirits. There’s one more piece of information that could warrant a downward revision to the marijuana firm’s potential revenue growth rate. For a start, this was the…

Read More

Cronos Group Stock Price to Suffer an Earnings Restatement Penalty

Cronos Group (TSX:CRON)(NASDAQ:CRON) stock price fell by 12% early on Wednesday to give up some of its near 13% gains on Tuesday after the marijuana firm said it will effect a 40% charge on its third quarter 2019 revenue and will make a similar adjustment in its restated Q1 2019 earnings results. Cronos will reduce its first-quarter and third-quarter revenues…

Read More

Should You Consider Aurora Cannabis (TSX:ACB) Stock at These Levels?

Though the leading pot stock Aurora Cannabis (TSX:ACB)(NYSE:ACB) showed some recovery recently, uncertainty might continue to weigh in. Its immense volatility might have worked in favour of the traders, but long-term investors have been brutally burned. The stock has lost more than 75% in the last 12 months. Aurora Cannabis’s poor Q2 show Aurora Cannabis yet again reported a loss…

Read More

Canopy Growth’s (TSX:WEED) Latest 62% Revenue Growth Isn’t Repeatable

Canopy Growth (TSX:WEED)(NYSE:CGC) stock soared over 15% on Friday after the cannabis firm released a strong earnings report that revealed a 62% sequential net revenue growth to $124 million for its fiscal Q3 2019 ended in December 2019. Such high double-digit growth rates, especially on a sequential quarter-over-quarter basis, deserve a huge celebration and should naturally drive the stock price…

Read More

Aurora Cannabis (TSX:ACB) Revenue Falls 26%: Time to Sell the Stock?

This past week, Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) released its earnings for the second quarter of 2020, and they were, predictably, bad. The company reported a 26% drop in net revenue along with a colossal $1.3 billion GAAP net loss. While the net loss was mostly due to a goodwill impairment charge, the company also reported a $80 million adjusted EBITDA loss that…

Read More

TFSA Investors: Buy Aphria (TSX:APHA) Stock

Cannabis grower and leading distributor Aphria’s (TSX:APHA)(NYSE:APHA) stock price could continue to surge and outperform industry peers in 2020, and I’m maintaining my positive outlook and reiterating a buy recommendation on this marijuana firm. In a November 2019 post, and while discussing three potential buys for 2020, I likened the stock’s potential payoff to that on a cannabis lottery ticket.…

Read More